Pharmacoepidemiology and Drug Safety (PDS)
PDS has established itself as the only truly focused international forum for papers on the expanding science and practice of pharmacoepidemiology, addressing issues on the safety, efficacy, proper use of and quality of prescription medicines. It also covers questions of data assembly and processing, the maintenance of large databases and their use of computerised dictionaries, the vexed questions of data privacy and confidentiality, and the increasing demand for studies of relative efficacy, effectiveness and cost effectiveness, and quality-of-life studies.
PDS is the official journal of ISPE; PDS is a MEDLINE and ISI listed journal. ISPE members receive online access to PDS as a member benefit.
PDS now contains some new and special features, in addition to the full-length primary research papers.
- Fast-track Publication for selected articles and early reports. The journal can now publish a peer-reviewed manuscript as early as 12 weeks from receipt, after granting full clinical, scientific, and statistical review.
- Current Awareness Service in each issue containing a bibliography of newly published material in the field of pharmacoepidemiology and drug safety.
- Annual Supplement containing highlights from International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
- New Editorial Features include structured abstracts and take home points for each paper.
- Guest editorials, commentaries and invited reviews encompassing scientific, medical, statistical and legal aspects of pharmacoepidemiology and post-marketing surveillance of drug safety.
Particular Areas of Interest Include:
- design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes;
- methods for detection and evaluation of drug-associated adverse events;
- assessments of risk and benefit in drug therapy;
- patterns of drug utilization;
- relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
- risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
For more information, click here.
For instructions for authors and submission guidelines, click here.